Estetrol and Drospirenone — Competitive Intelligence Brief

Estetrol and Drospirenone (Estetrol and Drospirenone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined oral contraceptive. Area: Contraception.

marketed Combined oral contraceptive Estrogen receptor; progesterone receptor Contraception Small molecule

Target snapshot

Estetrol and Drospirenone (Estetrol and Drospirenone) — Ospedale Policlinico San Martino. Estetrol and drospirenone work together as a hormonal contraceptive, with estetrol providing estrogenic activity and drospirenone providing progestagenic activity to prevent ovulation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Estetrol and Drospirenone TARGET	Estetrol and Drospirenone	Ospedale Policlinico San Martino	marketed	Combined oral contraceptive	Estrogen receptor; progesterone receptor
Ethinyl Estradiol-cyprosterone acetate	Ethinyl Estradiol-cyprosterone acetate	S.C.B. Medical College and Hospital	marketed	Oral contraceptive; combined estrogen-progestin	Estrogen receptor; progesterone receptor; androgen receptor (antagonist)
Agonist GnRH; estradiol Valerate; progesterone	Agonist GnRH; estradiol Valerate; progesterone	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	Hormone combination therapy; GnRH agonist with steroid hormones	GnRH receptor; estrogen receptor; progesterone receptor
Nomegestrol Acetate / Estradiol	Nomegestrol Acetate / Estradiol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, Estrogen receptor
placebo + ethinylestradiol/levonorgestrel	placebo + ethinylestradiol/levonorgestrel	HRA Pharma	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor
Levonorgestrel and ethinylestradiol	Levonorgestrel and ethinylestradiol	IVI Madrid	marketed	Combined oral contraceptive	Progesterone receptor (levonorgestrel); estrogen receptor (ethinylestradiol)
Drospirenone and Ethinyl Estradiol tablets	Drospirenone and Ethinyl Estradiol tablets	Hansoh BioMedical R&D Company	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined oral contraceptive class)

1. University of Palermo · 3 drugs in this class
2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
3. Organon and Co · 2 drugs in this class
4. HRA Pharma · 1 drug in this class
5. Hansoh BioMedical R&D Company · 1 drug in this class
6. Helsinki University Central Hospital · 1 drug in this class
7. Hoffmann-La Roche · 1 drug in this class
8. IVI Madrid · 1 drug in this class
9. Leiden University Medical Center · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class